OVARIAN CANCER and US: Merck

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label Merck. Show all posts
Showing posts with label Merck. Show all posts

Monday, April 16, 2012

media: Merck’s $1 billion deal includes phase 3 ovarian cancer therapeutic (Vintafolide/Endocyte)



Merck’s $1 billion deal includes phase 3 ovarian cancer therapeutic

 Merck (NYSE:MRK) has forged a deal with a biopharmaceutical company for its phase 3 platinum-resistant ovarian cancer treatment and nonsmall cell lung cancer in mid-stage development in a deal valued at up to $1 billion... Under the terms of the deal, Merck, through a subsidiary, will get worldwide rights to develop and commercialize vintafolide for ovarian cancer that’s resistant to platinum-based chemotherapy treatment. Endocyte (NASDAQ:ECYT), the Indiana-based cancer therapeutics developer, will receive a $120 million up-front payment and is eligible for milestone payments of up to $880 million if it achieves certain development, regulatory and commercialization milestones for vintafolide for a total of six cancer indications, according to a company statement......

"...The clinical trials for both maladies will also use etarfolatide, a noninvasive companion diagnostic imaging agent that is used to identify folate receptor positive tumor cells.....